Loading stock data…
Matinas BioPharma Holdings (MTNB)
$0.18
Market ClosedLast close Sep 8
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Matinas BioPharma Holdings, Inc. in the Healthcare sector is trading at $0.18 with a market capitalization of $5M. The stock is currently near its 52-week low of $0.17, remaining 68.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.94M↓ | -$1.60M↓ | -$1.58M↑ | -$1.84M↑ | -$1.95M |
| Net Income | -$1.92M↓ | -$1.91M↓ | -$1.53M↑ | -$5.25M↓ | -$1.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-351.09%
Volume
Today's trading volume
560,099
